Comera Life Sciences Holdings, Inc. (CMRA)
| Previous close | 0.0627 |
| Open | 0.0667 |
| Bid | 0.0000 x 2200 |
| Ask | 0.0000 x 1800 |
| Day's range | 0.0627 - 0.0800 |
| 52-week range | 0.0300 - 2.1700 |
| Volume | |
| Avg. volume | 200,206 |
| Market cap | 2.459M |
| Beta (5Y monthly) | 1.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2200 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireComera Life Sciences Appoints Dorothy Clarke to Board of Directors
Dorothy Clarke Dorothy Clarke WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced it appointed Dorothy Clarke to its board of directors. “Dorothy’s extensive experience will help Comera continue to deliver on its mission of delivering transformative solutions that have the potential to revolutionize the way
GlobeNewswireComera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights
– Final stage of technical evaluation near completion in Comera’s research collaboration with Regeneron, a leading U.S. biotechnology company – – Expanded and strengthened Comera’s global patent portfolio, broadening both geographic coverage and claims for core SQore excipient technology – – Completed previously announced $4.1 million private placement of shares of Comera’s common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders – WOBURN, Mass., N
- GlobeNewswire
Comera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery Conference
WOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today will present research demonstrating Comera’s SQore™ platform capabilities in the development of subcutaneous monoclonal antibody formulations at the PODD: Partnerships in Drug Delivery conference in Boston, Mass. Yuhong Zeng, Ph.D., Director of Formulation at Comera,
